1.Cost-effectiveness of lecanemab for early Alzheimer disease
Chaogang XIONG ; Junsong WEI ; Mengna AN ; Zijie DENG ; Lei DU ; Qian LEI ; Xin ZHANG ; Shengjie ZHANG ; Wenbing MA ; Weiyi FENG
China Pharmacy 2026;37(13):1735-1739
OBJECTIVE To evaluate the cost-effectiveness of lecanemab for early Alzheimer disease (AD) from a whole-society perspective. METHODS Based on data from the Clarity AD study, a global multicenter, randomized, double-blind, placebo-controlled study of lecanemab for early AD, a Markov model was developed according to the disease progression of AD, with a monthly cycle and a time horizon extending to 99% patient mortality. Quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were used as outcome indicators, with a willingness-to-pay (WTP) threshold set at twice China’s per capita gross domestic product (GDP) for 2025 (199 330.00 yuan/QALY). The model simulated the cost-effectiveness of lecanemab plus standard of care (SoC) versus placebo plus SoC for early AD. One-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analysis were employed to test the robustness of the results. RESULTS Compared with placebo plus SoC, the ICER for lecanemab plus SoC was 4 364 711.54 yuan/QALY. One-way sensitivity analysis showed that the hazard ratio for disease progression, the price of lecanemab, body weight, the monthly progression probability of mild cognitive impairment, and the discount rate were key parameters affecting model robustness. Results of the probabilistic sensitivity analysis showed that the probability of lecanemab being cost-effective was 0 at the current WTP threshold. Scenario analysis indicated that a price reduction of at least 94.88% would be required for lecanemab to fall below the WTP threshold. CONCLUSIONS At the current WTP threshold, lecanemab plus SoC is not cost-effective compared with placebo plus SoC for early AD.
2.Cost-effectiveness of lecanemab for early Alzheimer disease
Chaogang XIONG ; Junsong WEI ; Mengna AN ; Zijie DENG ; Lei DU ; Qian LEI ; Xin ZHANG ; Shengjie ZHANG ; Wenbing MA ; Weiyi FENG
China Pharmacy 2026;37(13):1735-1739
OBJECTIVE To evaluate the cost-effectiveness of lecanemab for early Alzheimer disease (AD) from a whole-society perspective. METHODS Based on data from the Clarity AD study, a global multicenter, randomized, double-blind, placebo-controlled study of lecanemab for early AD, a Markov model was developed according to the disease progression of AD, with a monthly cycle and a time horizon extending to 99% patient mortality. Quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were used as outcome indicators, with a willingness-to-pay (WTP) threshold set at twice China’s per capita gross domestic product (GDP) for 2025 (199 330.00 yuan/QALY). The model simulated the cost-effectiveness of lecanemab plus standard of care (SoC) versus placebo plus SoC for early AD. One-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analysis were employed to test the robustness of the results. RESULTS Compared with placebo plus SoC, the ICER for lecanemab plus SoC was 4 364 711.54 yuan/QALY. One-way sensitivity analysis showed that the hazard ratio for disease progression, the price of lecanemab, body weight, the monthly progression probability of mild cognitive impairment, and the discount rate were key parameters affecting model robustness. Results of the probabilistic sensitivity analysis showed that the probability of lecanemab being cost-effective was 0 at the current WTP threshold. Scenario analysis indicated that a price reduction of at least 94.88% would be required for lecanemab to fall below the WTP threshold. CONCLUSIONS At the current WTP threshold, lecanemab plus SoC is not cost-effective compared with placebo plus SoC for early AD.
3.Microbiota distribution in oral and esophageal sites of esophageal squamous cell carcinoma patients
Jinyu KONG ; Xingyue FENG ; Mengfan QIAN ; Jian WANG ; Wei SUN ; Yiwen LIU ; Ruonan LI ; Shegan GAO
Acta Universitatis Medicinalis Anhui 2026;61(7):1296-1304
ObjectiveTo investigate the distribution characteristics and correlation of paired oral and esophageal microbiota in patients with esophageal squamous cell carcinoma (ESCC). MethodsA total of 46 pathologically confirmed ESCC patients were enrolled, and oral swabs and cancerous tissue samples were collected. The microbial composition was analyzed using 16S rRNA gene sequencing, and bioinformatics methods were employed to compare the microbiota diversity, compositional differences, and correlations between the two sites. ResultsThe Alpha diversity of the oral microbiota in ESCC patients was significantly higher than that of their esophageal microbiota, though the overall community structure was similar between the two sites. LEfSe analysis revealed that Spirochaetes, Prevotella, Catonella, Enterococcus, Fusobacterium periodonticum, Veillonella parvula, Capnocytophaga sputigena, and Neisseria subflava were significantly enriched in ESCC tumor tissues. In contrast, Actinobacteria, Proteobacteria, Streptococcus, Neisseria, Haemophilus, Streptococcus mitis, Haemophilus parainfluenzae, Porphyromonas gingivalis, Haemophilus haemolyticus, and Prevotella tannerae were significantly enriched in the oral cavity. Correlation analysis demonstrated significant associations between the two sites at taxonomic levels such as Spirochaetes, Treponema, Granulicatella elegans, Neisseria macacae, Treponema amylovorum, Fusobacterium periodonticum, and Neisseria meningitidis (P<0.05). ConclusionThe oral and esophageal microbiota in ESCC patients exhibit both distinct differences and similarities. Oral microbiota may influence the esophageal microenvironment through migration or local immune modulation.
4.Creation and Exploration of the"Organized Fill-in-the-Blank Format"Disci-pline Construction Model for Forensic Medicine in the New Era
Zhi-Wen WEI ; Hong-Xing WANG ; Jun-Hong SUN ; Hao-Liang FAN ; Hong-Liang SU ; Le-Le WANG ; Wen-Ting HE ; Zhe CHEN ; Jie ZHANG ; Xiang-Jie GUO ; Ji LI ; Geng-Qian ZHANG ; Xin-Hua LIANG ; Jiang-Wei YAN ; Qiang-Qiang ZHANG ; Cai-Rong GAO ; Ying-Yuan WANG ; Hong-Wei WANG ; Jun XIE ; Bo-Feng ZHU ; Ke-Ming YUN
Journal of Forensic Medicine 2025;41(1):25-29
Forensic medicine has been designated as a first-level discipline,presenting new opportunities and challenges for the development of forensic medicine.Since the 1980s,the establishment of foren-sic medicine discipline and the cultivation of high-level forensic talents have become hot topics in the development of forensic medicine in China.Since the 13th Five-Year Plan,the forensic team of Shanxi Medical University has been aiming at the forefront,proposing the development goals of"Five First-class"and the discipline development path"Six Major Achievements".It has selected benchmark disci-plines,identified gaps in disciplinary development,unified thoughts,formulated completion timelines,concentrated superior resources,assigned tasks to individuals,and created an"Organized Fill-in-the-Blank Format"forensic medicine discipline construction model with the characteristics of the new era.The construction model of forensic medicine has achieved good results in the goals,discipline frame-work,scientific research,talent cultivation,discipline team and platform construction,forming a rela-tively complete discipline construction and management system,and accumulating valuable experience for the construction of first-level discipline and high-level talent cultivation of forensic medicine.
5.Sirtuin 3 Attenuates Acute Lung Injury by Decreasing Ferroptosis and Inflammation through Inhibiting Aerobic Glycolysis.
Ke Wei QIN ; Qing Qing JI ; Wei Jun LUO ; Wen Qian LI ; Bing Bing HAO ; Hai Yan ZHENG ; Chao Feng HAN ; Jian LOU ; Li Ming ZHAO ; Xing Ying HE
Biomedical and Environmental Sciences 2025;38(9):1161-1167
6.Associations of Exposure to Typical Environmental Organic Pollutants with Cardiopulmonary Health and the Mediating Role of Oxidative Stress: A Randomized Crossover Study.
Ning GAO ; Bin WANG ; Ran ZHAO ; Han ZHANG ; Xiao Qian JIA ; Tian Xiang WU ; Meng Yuan REN ; Lu ZHAO ; Jia Zhang SHI ; Jing HUANG ; Shao Wei WU ; Guo Feng SHEN ; Bo PAN ; Ming Liang FANG
Biomedical and Environmental Sciences 2025;38(11):1388-1403
OBJECTIVE:
The study aim was to investigate the effects of exposure to multiple environmental organic pollutants on cardiopulmonary health with a focus on the potential mediating role of oxidative stress.
METHODS:
A repeated-measures randomized crossover study involving healthy college students in Beijing was conducted. Biological samples, including morning urine and venous blood, were collected to measure concentrations of 29 typical organic pollutants, including hydroxy polycyclic aromatic hydrocarbons (OH-PAHs), bisphenol A and its substitutes, phthalates and their metabolites, parabens, and five biomarkers of oxidative stress. Health assessments included blood pressure measurements and lung function indicators.
RESULTS:
Urinary concentrations of 2-hydroxyphenanthrene (2-OH-PHE) ( β = 4.35% [95% confidence interval ( CI): 0.85%, 7.97%]), 3-hydroxyphenanthrene ( β = 3.44% [95% CI: 0.19%, 6.79%]), and 4-hydroxyphenanthrene (4-OH-PHE) ( β = 5.78% [95% CI: 1.27%, 10.5%]) were significantly and positively associated with systolic blood pressure. Exposures to 1-hydroxypyrene (1-OH-PYR) ( β = 3.05% [95% CI: -4.66%, -1.41%]), 2-OH-PHE ( β = 2.68% [95% CI: -4%, -1.34%]), and 4-OH-PHE ( β = 3% [95% CI: -4.68%, -1.29%]) were negatively associated with the ratio of forced expiratory volume in the first second to forced vital capacity. These findings highlight the adverse effects of exposure to multiple pollutants on cardiopulmonary health. Biomarkers of oxidative stress, including 8-hydroxy-2'-deoxyguanosine and extracellular superoxide dismutase, mediated the effects of multiple OH-PAHs on blood pressure and lung function.
CONCLUSION
Exposure to multiple organic pollutants can adversely affect cardiopulmonary health. Oxidative stress is a key mediator of the effects of OH-PAHs on blood pressure and lung function.
Humans
;
Oxidative Stress/drug effects*
;
Male
;
Cross-Over Studies
;
Female
;
Young Adult
;
Environmental Pollutants/toxicity*
;
Environmental Exposure/adverse effects*
;
Biomarkers/blood*
;
Adult
;
Blood Pressure/drug effects*
;
Polycyclic Aromatic Hydrocarbons/urine*
;
Beijing
7.Consistency of ultrasound diagnosis of abnormal placenta in singleton pregnancy and its relationship with adverse pregnancy outcome
Jing ZHAO ; Qian ZHANG ; Wei FENG ; Lina ZHANG ; Xianquan SHI
China Medical Equipment 2025;22(6):64-69
Objective:To explore ultrasound technique in relationship between three common abnormal placentas in singleton pregnancy,which included battledore placenta,velamentous placenta and circumvallate placenta,and clinically adverse pregnancy outcome.Methods:A retrospective study was conducted on the case documents of 330 singleton patients with abnormal placenta admitted and confirmed at Beijing Friendship Hospital from January 2020 to December 2024.Based on the morphology of abnormal placenta and the location of the umbilical cord attached to the placenta,they were divided into battledore placenta group(126 cases),velamentous placenta group(139 cases),and circumvallate placenta group(65 cases).Additionally,197 pregnant women with normal placenta who gave birth during the same period were selected as the normal placenta group.The perinatal outcomes of abnormal placenta and normal placenta were compared.Results:The coincidence rates of ultrasound diagnosis for the three abnormal placentas,which included battledore placenta,velamentous placenta and circumvallate placenta,were respectively 40.5%(51/126),46.0%(64/139)and 58.5%(38/65).The proportions of adverse pregnancy outcomes caused by three abnormal placentas were respectively 49.2%,69.8%and 47.7%,and the differences were statistically significant(x2=12.857,53.575,7.258,P<0.005).The quantity of adverse pregnancy outcome caused by velamentous placenta was the largest,which included increase of cesarean section rate,premature birth,fetal growth restriction,placental adhesions,postpartum hemorrhage,and neonatal asphyxia.Conclusion:All three kinds of abnormal placenta can increase the risk of adverse perinatal outcomes.It is important to pay attention to the situation of placenta in ultrasound during pregnancy,so as to make early diagnosis,and guide clinical work to adopt effective measures,which can reduce the occurrence of adverse pregnancy outcomes.
8.Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma
Hui ZHANG ; Chenyu JIAO ; Changxian LI ; Feng ZHANG ; Feng CHENG ; Xiaofeng QIAN ; Ke WANG ; Liyong PU ; Chuanyong ZHANG ; Lianbao KONG ; Donghua LI ; Ping WANG ; Aihua YAO ; Xiaofeng WU ; Wei YOU ; Xuehao WANG ; Xiangcheng LI
Chinese Journal of Surgery 2025;63(4):322-330
Objective:To evaluate the survival benefit of surgical treatment for intrahepatic cholangiocarcinoma.Methods:This study is conducted based on the hepatobiliary tumor registry database. From May 2009 to December 2022,a total of 704 patients who were initially diagnosed with intrahepatic cholangiocarcinoma and underwent liver resection were consecutively enrolled at the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University. Among them,there were 380 males and 324 females,aged ( M(IQR)) 61(15) years(range:27 to 88 years). Twenty-six (3.7%) patients received neoadjuvant therapy before surgery. The overall survival(OS) and disease-free survival(DFS) rates were estimated by life table method, and Kaplan-Meier survival curves were plotted. Log-rank test was used to compare the survival difference among tumor-node-metastasis(TNM) staging or three periods. The OS and DFS differences among lymph node groups or adjuvant treatment groups were quantified as HR with 95% CI estimated using Cox proportional-hazards model with adjustment for prognostic factors. Results:Among the 704 patients,349 cases(49.6%) underwent major hepatectomy (≥3 segments),331(47.0%) had lymph node resection during surgery,and 524 cases(74.4%) achieved R0 resection. The morbidity of Clavien-Dindo grade Ⅲ or higher complications was 16.5%(116/704),with a mortality rate of 3.0%(21/704) within 30 days post-surgery. The median OS time was 27.1 months, and the OS rates at 1-,3-,5- and 10-year were 69.1%, 42.4%,34.1% and 24.5%,respectively. The median DFS time was 10.5 months,and the corresponding DFS rates were 46.0%,25.4%,21.9% and 16.9%,respectively. According to the 8 th edition of AJCC staging system, the 5-year survival rates for ⅠA,ⅠB,Ⅱ,ⅢA,ⅢB and Ⅳ were 68.4%, 43.2%, 30.3%,32.2%,14.0% and 0,respectively. The corresponding DFS rates were 55.8%, 28.1%,13.8%,21.2%,3.3% and 0,respectively. There were no statistically significant differences of OS or DFS between stage ⅠB and Ⅱ, stage ⅠB and ⅢA, or between stage Ⅱ and ⅢA(Log-rank test:all P>0.05),while there were significant differences of OS and DFS among other stages(Log-rank test:all P<0.05). Using Cox model with adjustment for prognostic factors, there were no statistically significant differences of OS and DFS between non-lymphadenectomy group or the biopsy-N0 group and dissection-N0 group(both P>0.05). However,the overall and disease-free survival of the biopsy-N1 group or dissection-N1 group were worse than those of dissection-N0 group(both P<0.05),with overall survival being better in dissection-N1 group than biopsy-N1 group( P=0.017). Overall survival in the period from 2019 to 2022 were significantly superior to that during the periods from 2009 to 2013 and 2014 to 2018(both P<0.01). Adjusting for prognostic factors, the disease-free and overall survival of the postoperative adjuvant therapy group were significantly better than those of the observation group in the period 2019 to 2022(both P<0.01). Conclusions:Surgery remains a milestone for achieving long-term survival for patients with intrahepatic cholangiocarcinoma. Regional lymph node dissection is required for patients with lymph node metastasis. Adjuvant therapy can significantly reduce tumor recurrence and prolong overall survival.
9.Expert consensus on intraoperative repositioning for patients with spine fracture and dislocation (version 2025)
Dongmei BIAN ; Ke SUN ; Ningbo CHEN ; Caixia BAI ; Miao WANG ; Yafeng QIAO ; Fei WANG ; Hong WANG ; Feng TIAN ; Mei YAN ; Meng BAI ; Linjuan ZHANG ; Liyan ZHAO ; Yaqing CUI ; Xue JIANG ; Leling FENG ; Ning NING ; Junqin DING ; Lan WEI ; Yonghua ZHAI ; Yu ZENG ; Zengmei ZHANG ; Jiqun HE ; Fenggui BIE ; Hong CHEN ; Zengyan WANG ; Li LI ; Li ZHANG ; Yaying ZHOU ; Bing SHAO ; Ying WANG ; Caixia XIE ; Yanfeng YAO ; Jingjing AN ; Wen SHI ; Xiongtao LIU ; Xiaoyan AN ; Ning NAN ; Lan LI ; Xiaohui GOU ; Qiaomei LI ; Xiuting WU ; Yuqin ZHANG ; Jing LIU ; Fusen XIANG ; Xu XU ; Na MEI ; Jiao ZHOU ; Shan FAN ; Qian WANG ; Shuixia LI
Chinese Journal of Trauma 2025;41(2):138-147
Spine fracture and dislocation are common traumatic spinal conditions that often require surgical intervention due to compromised spinal stability. Surgical approaches include anterior, posterior, and combined anterior-posterior spinal procedures. According to the specific surgical requirements, patients may be placed in the prone position or repositioned between prone and supine positions during surgery. Intraoperative repositioning has become an essential step in patient positioning. However, during repositioning, patients with spinal fracture and dislocation are at increased risk for complications such as hemodynamic instability, nerve injury, and pressure injuries to the skin and soft tissue. Notably, due to the instability of the spinal cord, even minor manipulations can further exacerbate the damage, potentially leading to severe outcomes like paraplegia. Although the current clinical guidelines provide instructive recommendations for standard position, there remains no specific protocols for intraoperative repositioning in patients with spine fracture and dislocation. With a concern for the lack of clinical studies on positioning techniques, risk prevention, and operational norms for special patients, no applicable guidelines or standards are available. A consensus was required to provide clinical reference, meet the requirements of surgical treatment, and minimize the safety risks of patients caused by improper placement of positions. Professional Committee of Operating Room Nursing of Shaanxi Nursing Association organized experts in nursing management and operating room nursing from major hospitals across China to formulate Expert consensus on intraoperative repositioning for patients with spinal fracture and dislocation ( version 2025). The consensus provides 11 recommendations covering pre-repositioning preparation, intraoperative maneuvers, and post-repositioning observation, aiming to provide references for clinical standardization of the intraoperative repositioning process and protection of patients′ safety.
10.Develop and assessment of a predictive model for the first-course efficacy of acute myeloid leukemia
Feng ZHU ; Yile ZHOU ; Yi ZHANG ; Liping MAO ; De ZHOU ; Liya MA ; Chunmei YANG ; Wenjuan YU ; Xingnong YE ; Juying WEI ; Haitao MENG ; Min YANG ; Wenyuan MAI ; Jiejing QIAN ; Yanling REN ; Yinjun LOU ; Jian HUANG ; Gaixiang XU ; Wanzhuo XIE ; Hongyan TONG ; Huafeng WANG ; Jie JIN
Chinese Journal of Hematology 2025;46(4):336-342
Objective:To identify the relevant factors for the first-course remission of acute myeloid leukemia (AML) and to develop a predictive model as well as assess its predictive capability.Methods:Clinical data of 749 patients newly diagnosed with AML admitted to the Department of Hematology, the First Affiliated Hospital, Zhejiang University, School of Medicine from January 1, 2019, to April 30, 2023, were collected and randomly divided into training and validation sets. Multivariate logistic regression analysis was conducted to determine variables associated with complete remission in the first course of induction therapy, and a predictive model was established based on these variables. The receiver operating characteristic (ROC) curve of the predictive model was plotted, and the area under the curve (AUC) was calculated.Results:The indicators predicting the first remission course included peripheral blood white blood cell count during onset, CBF::MYH11 fusion gene, CEBPA bZIP region mutation, myelodysplastic syndrome-related gene mutation, and induction chemotherapy regimen selection as independent factors for the first remission course. The model’s area under the training and validation curves was 0.738 (95% CI: 0.696-0.780) and 0.726 (95% CI: 0.650-0.801), respectively. The Hosmer-Lemeshow test results yielded P-values of 0.993 and 0.335, respectively. Conclusion:In this study, the developed model demonstrates a strong predictive capability for the efficacy of the first course of patients with AML, providing valuable guidance to clinicians in assessing patient prognosis and selecting appropriate treatment strategies.

Result Analysis
Print
Save
E-mail